Passive Immunity Trial for Our Nation to Treat COVID-19 in Hospitalized Adults
The purpose of this study is to test the safety and efficacy of convalescent donor plasma to treat COVID-19 in hospitalized adults in a randomized, placebo-controlled setting. The effect of convalescent plasma will be compared to placebo on clinical outcomes, measured using the COVID-19 7-point Ordinal Clinical Progression Outcomes Scale at Day 15, among adults with COVID-19 requiring hospitalization.
- Eligible Ages
- Over 18 Years
- Eligible Genders
- Accepts Healthy Volunteers
- Age greater than or equal to 18 years 2. Currently hospitalized or in an emergency department with anticipated hospitalization 3. Symptoms of acute respiratory infection, defined as one or more of the following: 1. Cough 2. Chills, or a fever (greater than 37.5° C or 99.5° F) 3. Shortness of breath, operationalized as a patient having any of the following: i. Subjective shortness of breath reported by a patient or surrogate. ii. Tachypnea with respiratory rate of greater than 22 breaths per minute iii. Hypoxemia, defined as SpO2 less than 92% on room air, new receipt of supplemental oxygen to maintain SpO2 greater than or equal to 92%, or increased supplemental oxygen to maintain SpO2 greater than or equal to 92% for a patient on chronic oxygen therapy 4. Laboratory-confirmed SARS-CoV-2 infection within the past 14 days
- Prisoner 2. Unable to randomize within 14 days after onset of acute respiratory infection symptoms 3. Patient, legal representative, or physician not committed to full support (Exception: a patient who will receive all supportive care except for attempts at resuscitation from cardiac arrest will not be excluded.) 4. Inability to be contacted on Day 29-36 for clinical outcome assessment 5. Receipt of any SARS-CoV-2 passive immunity therapy, such as convalescent plasma, monoclonal antibodies, or pooled immunoglobulin, in the past 30 days 6. Contraindications to transfusion or history of prior reactions to transfused blood products 7. Plan for hospital discharge within 24 hours of enrollment 8. Previous enrollment in this trial 9. Previous laboratory-confirmed SARS-CoV-2 infection before the current illness 10. Enrollment in another clinical trial evaluating monoclonal antibodies, convalescent plasma, or another passive immunity therapy 11. Prior receipt of SARS-CoV-2 vaccine
- Phase 3
- Study Type
- Intervention Model
- Parallel Assignment
- Intervention Model Description
- Eligible participants will be randomized 1:1 to convalescent plasma versus lactated Ringer's solution with multivitamins. Randomization will be completed in permuted blocks and stratified by site, gender, and age. Participants, treating clinicians and outcomes assessors will all be blinded to study group assignment. Study personnel will not be blinded to the study group assignment.
- Primary Purpose
- Triple (Participant, Care Provider, Outcomes Assessor)
pathogen reduced SARS-CoV-2 convalescent plasma
|Transfusion of convalescent plasma will be administered by clinical or research personnel while the participant is hospitalized on Study Day 0. Plasma will be administered at a rate of 500 mL/hour and will be administered within 12 hours of randomization.||
|Participants randomized to the control group will receive 250mL of Lactate Ringers containing multivitamins intravenously on Day 1 as a placebo.||
- Vanderbilt University Medical Center
Study ContactAmanda J Bistran-Hall
After being informed about the study and potential risks, participants confirmed to meet all eligibility criteria who have provided informed consent will be randomized 1:1 to convalescent plasma versus placebo. Transfusion of convalescent plasma or placebo will be administered by clinical or research personnel while the patient is hospitalized on Study Day 1. On Study Days 1-7, participants will be monitored for adverse reactions to the transfusion. Research personnel will also assess patients at Day 14 and Day 28; these assessments will be completed by phone if the participant has been discharged from the hospital.